AlphaYou
Overview
Key stats
Fundamentals Sep 9- Open
- $153.99
- 52-wk high
- $186.12
- High
- $156.82
- 52-wk low
- $122.14
- Low
- $151.77
- Prev close
- $155.64
- Mkt cap
- $15.77B
- P/E
- 22.7x
- Volume
- 804.8K
- Fwd P/E
- 15.5x
- Beta
- 0.38
- P/S
- 4.7x
- P/B
- 4.3x
- Profit margin
- +20.9%
- Op margin
- +22.2%
- ROE
- +22.1%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in 25.5% above what analysts expected.
Earnings per share
$1.88 expected
Reports Oct 27, 2026, in 47 days
EPS expected
$2.07 to $3.39
Revenue expected
23 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $794.9M | $805.5M | $814.5M | $959.0M |
| Cost of what it sold | $14.0M | $17.6M | $13.8M | $23.2M |
| Gross profit | $780.9M | $787.9M | $800.7M | $935.8M |
| What it spent | ||||
| Research and development | $250.0M | $258.2M | $296.2M | $326.7M |
| Sales and admin | $291.6M | $301.8M | $318.5M | $439.7M |
| Other operating costs | — | $17.0M | — | $16.4M |
| Total operating expenses | $541.9M | $577.0M | $614.7M | $782.8M |
| What was left | ||||
| Operating profit | $239.0M | $210.9M | $186.0M | $153.0M |
| Interest on debt | — | — | — | $2.9M |
| Profit before tax | $291.8M | $239.4M | $246.8M | $162.2M |
| Tax | $82.3M | $85.7M | $48.9M | $17.8M |
| Net profit | $209.5M | $153.7M | $197.9M | $144.4M |
| EBITDA | $299.5M | $235.4M | $193.3M | $189.9M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
BullishAug 26
Macro
32 macro signals shaping NBIX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results